133 related articles for article (PubMed ID: 38534931)
21. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
[TBL] [Abstract][Full Text] [Related]
22. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
23. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
Jasem J; Fisher CM; Amini A; Shagisultanova E; Rabinovitch R; Borges VF; Elias A; Kabos P
J Natl Compr Canc Netw; 2017 Apr; 15(4):494-503. PubMed ID: 28404760
[No Abstract] [Full Text] [Related]
24. A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands.
Simons MJHG; Machielsen PM; Spoorendonk JA; Ignacio T; Drost PB; Jacobs T; de Jongh FE
J Med Econ; 2024; 27(1):445-454. PubMed ID: 38436289
[TBL] [Abstract][Full Text] [Related]
25. Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.
Torres S; Trudeau M; Gandhi S; Warner E; Verma S; Pritchard KI; Petrella T; Hew-Shue M; Chao C; Eisen A
Oncologist; 2018 Jul; 23(7):768-775. PubMed ID: 29371476
[TBL] [Abstract][Full Text] [Related]
26. Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center.
Losk K; Freedman RA; Laws A; Kantor O; Mittendorf EA; Tan-Wasielewski Z; Trippa L; Lin NU; Winer EP; King TA
Breast Cancer Res Treat; 2021 Jan; 185(1):215-227. PubMed ID: 32939592
[TBL] [Abstract][Full Text] [Related]
27. The Impact of Genomic Profiling on Adjuvant Therapy Recommendation in Postmenopausal Women with ER-Positive, T1-2 Breast Cancer: Can Genomic Profiling Eliminate the Need for Sentinel Lymph Node Biopsy?
Lee E; Tweed C; Mylander C; Martino L; Rosman M; Huerta N; Waite K; Tafra L; Jackson RS
Clin Breast Cancer; 2021 Dec; 21(6):e731-e737. PubMed ID: 34006481
[TBL] [Abstract][Full Text] [Related]
28. Breast Cancers of Special Histologic Subtypes Are Biologically Diverse.
Tadros AB; Wen HY; Morrow M
Ann Surg Oncol; 2018 Oct; 25(11):3158-3164. PubMed ID: 30094484
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-receptor-positive, axillary lymph-node positive breast cancer.
Hannouf MB; Xie B; Brackstone M; Zaric GS
Pharmacoeconomics; 2014 Feb; 32(2):135-47. PubMed ID: 24288208
[TBL] [Abstract][Full Text] [Related]
30. Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score.
Jerevall PL; Brock J; Palazzo J; Wieczorek T; Misialek M; Guidi AJ; Wu Y; Erlander MG; Zhang Y; Schnabel CA; Goss PE; Horick N; Sgroi DC
Breast Cancer Res Treat; 2019 Jan; 173(2):375-383. PubMed ID: 30350269
[TBL] [Abstract][Full Text] [Related]
31. Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec.
Hassan S; Younan R; Patocskai E; Provencher L; Poirier B; Sideris L; Dubé P; Mihalcioiu C; Chabot-Blanchet M; Guertin MC; Boileau JF; Robidoux A
Oncologist; 2022 Oct; 27(10):822-831. PubMed ID: 35830543
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.
Pérez-Garcia J; Cortés J; Metzger Filho O
Oncologist; 2019 Aug; 24(8):1041-1047. PubMed ID: 30578311
[TBL] [Abstract][Full Text] [Related]
33. Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer.
Hillyar C; Rizki H; Abbassi O; Miles-Dua S; Clayton G; Gandamihardja T; Smith S
Cureus; 2020 Apr; 12(4):e7552. PubMed ID: 32382456
[TBL] [Abstract][Full Text] [Related]
34. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(10):1-234. PubMed ID: 32284770
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of 21-gene recurrence score assay for hormone receptor-positive, lymph node-negative breast cancer in early stage.
Yu-Qing Y; Lei W; Mei-Ling H; Jing-Jing X; Mei-Chen W; Jiang W; Jun-Sheng H; Rui L; Nan-Lin L
Exp Mol Pathol; 2019 Jun; 108():150-155. PubMed ID: 31026440
[TBL] [Abstract][Full Text] [Related]
36. Associations between use of the 21-gene recurrence score assay and chemotherapy regimen selection in a statewide registry.
Henry NL; Braun TM; Ali HY; Munir K; Silver SM; Gorski DH; Breslin TM; Griggs JJ
Cancer; 2017 May; 123(6):948-956. PubMed ID: 27787892
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
Hu G; Hu G; Zhang C; Lin X; Shan M; Yu Y; Lu Y; Niu R; Ye H; Wang C; Xu C
BMC Cancer; 2020 Feb; 20(1):136. PubMed ID: 32085753
[TBL] [Abstract][Full Text] [Related]
38. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.
Lyman GH; Cosler LE; Kuderer NM; Hornberger J
Cancer; 2007 Mar; 109(6):1011-8. PubMed ID: 17311307
[TBL] [Abstract][Full Text] [Related]
39. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
[TBL] [Abstract][Full Text] [Related]
40. Real-world economic value of a 21-gene assay in early-stage breast cancer.
Waintraub SE; McNamara D; Graham DMA; Pecora AL; Min J; Wu T; Noh HG; Connors J; Pe Benito R; Choi K; Schultz E; Goldberg SL
Am J Manag Care; 2017 Dec; 23(12):e416-e420. PubMed ID: 29261249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]